Triptans in the treatment of migraine: Drug selection by means of the SOJA method

Expert Opinion on Pharmacotherapy

Volumn 8, Issue SUPPL. 1, 2007, Pages

  Janknegt, Robert ^a  

^a Sittard Geleen Heerlen   (Netherlands)

Author keywords

Drug selection; Migraine; SOJA; Triptans

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANTIMIGRAINE AGENT; CAFFEINE; CIMETIDINE; CLARITHROMYCIN; ELETRIPTAN; ERGOTAMINE; ERGOTAMINE DERIVATIVE; ERYTHROMYCIN; FLUVOXAMINE; FROMIREX; FROVATRIPTAN; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; METOCLOPRAMIDE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROPRANOLOL; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIZATRIPTAN; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLMITRIPTAN;

AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; COORDINATION DISORDER; CORONARY ARTERY CONSTRICTION; DECISION SUPPORT SYSTEM; DIZZINESS; DOCUMENTATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERREFLEXIA; HYPERTENSION; MIGRAINE; NAUSEA; NETHERLANDS; PROSPECTIVE STUDY; SCORING SYSTEM; SEROTONIN SYNDROME; SINGLE DRUG DOSE; SKIN MANIFESTATION; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; WEAKNESS;

EID: 35448947909     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.S1.S15     Document Type: Article

References (114)

1. GOADSBY PJ: A triptan too far? (Editorial). J. Neurol. Neurosurg. Psychiatry (1998) 64:143-147.
2. FERRARI MD: Migraine. Lancet (1998) 351:1043-1051.
3. JANKNEGT R, STEENHOEK A: The system of objectified judgement analysis. A tool in rational drug selection for formulary purposes. Drugs (1997) 53:550-562.
4. FERNANDEZ FJ, JANSAT JM, COBARROCAS X et al.: Absolute bioavailability of oral and subcutaneous almotriptan. Cephalalgia (1999) 19:363.
5. CABARROCAS X, WARRINGTON SJ, JANSAT JM et al.: Pharmacokinetics and tolerability of oral almotriptan in the elderly. Cephalalgia (1999) 19:363.
6. 1B/1D agonist, in healthy volunteers. Headache (1998) 38:381.
7. MCENROE JD, FLEISHAKER JC: Clinical pharmacokinetics if almotriptan, a serotonin 5HT 1B/1D receptor agonist for the treatment of migraine. Clin. Pharmacokinet. (2005) 44:237-246.
8. 1D-like' receptor partial agonist. Cephalalgia (1997) 17:414-415.
9. JOHNSON BF, SHAH A, LAW G: The absorption kinetics of eletriptan in migraineurs. Headache (1997) 37:315.
10. KEMPSFORD RD, HOKE JF, HUFFMAN CS: The safety, tolerability and pharmacokinetics of oral naratriptan in healthy subjects. Headache (1997) 37:316.
11. FUSEAU E, BAILLE P, KEMPFFORD RD: A study to detemine the absolute oral bioavailability of naratriptan. Cephalalgia (1997) 17:417 (Abstract 07-A15).
12. SCIBERRAS DG, POLVINO WJ, GERTZ BJ et al.: Initial human experience with rizatriptan: a novel 5HT1D agonist. Br. J. Clin. Pharmacol. (1997) 43:49-54.
13. VYAS KP, HALPIN RA, GEER LA et al.: Disposition and pharmacokinetics of the antimigraine drug rizatriptan in humans. Drug Metab. Disp. (2000) 28:89-95.
14. CUTLER NR, JHEE SS, MAJUMDAR AK et al.: Pharmacokinetics of rizatriptan tablets during and between migraine attacks. Headache (1999) 39:264-269.
15. VISSER WH, BURGGRAAF J, MULLER LM et al.: Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin. Pharmacol. Ther. (1996) 60:452-460.
16. LACEY LF, HUSSEY EK, FOWLER PA: Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur. J. Clin. Pharmacol. (1995) 47:543-548.
17. DUQUESNOY C, MARNET JP, SUMNER D et al.: Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur. J. Pharm. Sci. (1998) 6:99-104.
18. SRAMEK JJ, HUSSEY EK, CLEMENTS B et al.: Oral sumatriptan pharmacokinetics in the migraine state. Clin. Drug Invest. (1999) 17:137-144.
19. KUNKA RL, HUSSEY EK, SHAW S et al.: Safety, tolerability and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. Cephalalgia (1997) 17:532-540.
20. MOORE KHP, HUSSEY EK, SHAW S et al.: Safety, tolerability and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia (1997) 17:541-550.
21. DIXON RM, MEIRE HB, EVANS DH et al.: Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia (1997) 17:639-646.
22. PECK RW, SEABER EJ, DIXON RM et al.: The pharmacodynamics and pharmacokinetics of the 5HT 1B/1D agonist zolmitriptan in healthy young and elderly men and women. Clin. Pharmacol. Ther. (1998) 63:342-353.
23. DIXON R, FRENCH S, KEMP J et al.: Effect of hepatic impairment on the pharmacokinetics of zolmitriptan. J. Clin. Pharmacol. (1998) 38:694-701.
24. SEABER E, ON N, DIXON RM et al.: The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan. Br. J. Clin. Pharmacol. (1997) 43:579-587.
25. DIXON R, WARRANDER A: The clinical pharmacokinetics of zolmitriptan. Cephalalgia (1997) 17(Suppl. 218):15-20.
26. MICROMEDEX2006.
27. SCHWARTZ CE: A surfait of serotonin: sumatriptan and serotinergic antidepressants. Arch. Intern. Med. (1999) 159:1141.
28. PASCUAL J: Almotriptan: a novel 5-HT 1B/D agonist for the symptomatic treatment of migraine. Expert Rev. Neurother. (2001) 1:20-27.
29. HYLAND R, JONES BC, MCCLEVERTY Pet al.: In vitro metabolism of eletriptan in human liver microsomes. Cephalalgia (1998) 18:412.
30. PERRY CM, MARKHAM A: Sumatriptan. An updated review of its use in migraine. Drugs (1998) 55:889-922.
31. HAARST AD VAN, VAN GERVEN JM, COHEN AF et al.: The effects of moclobemide on the pharmacokinetics of the 5-HT 1B/1D agonist rizatriptan in healthy volunteers. Br. J. Clin. Pharmacol. (1999) 48:190-196.
32. SHADLE CR, LIU G, GOLDBERG MR: A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers. J. Clin. Pharmacol. (2000) 40:309-315.
33. ROLAN P: Potential drug interactions with the novel antimigraine compound zolmitriptan. Cephalalgia (1997) 17(Suppl. 18):21-27.
34. SEABER EJ, RIDOUT G, LAYTON G et al.: The novel antimigraine compound zolmitriptan has no clinically significant interactions with paracetamol or metoclopramide. Eur. J. Clin. Pharmacol. (1997) 53:229-234.
35. SMITH DA, CLEARY EW, WATKINS S et al.: Zolmitriptan does not interact with fluoxetine in healthy volunteers. Int. J. Clin. Pharmacol. Ther. (1998) 36:301-305.
36. PECK RW, SEABER EJ, DIXON R et al.: The interaction between propranolol and the novel antimigraine agent sumatriptan. Br. J. Clin. Pharmacol. (1997) 44:595-599.
37. SPENCER CM, GUNASEKARA NS, HILLS C: Zolmitriptan. A review of its use in migraine. Drugs (1999) 58:347-374.
38. DOWSON A, MASSIOU H, LAÍNEZ M et al.: Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia (2002) 22:453-461.
39. SPIERINGS ELH, GOMEZ-MANCILLA B, GROSZ DE et al.: Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine. Arch. Neurol. (2001) 58:944-950.
40. ALLAIS G, ACUTO G, CABARROCAS X et al.: Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol. Sci. (2006) 27:S193-S197.
41. GARCIA-RAMOS G, MACGREGOR EA, HILLIARD B et al.: Comparative efficacy of eletriptan vs naratriptan in the acute treatment of migraine. Cephalalgia (2003) 23:869-876.
42. GOADSBY PJ, FERRARI MD, OLESEN J et al.: Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology (2000) 54:156-163.
43. SANDRINI G, FÄRKKILÄ M, BURGESS G et al.: Eletriptan vs sumatriptan. A double-blind, placebo-controlled, multiple migraine attack study. Neurology (2002) 59:1210-1217.
44. MATHEW NT, SCHOENEN J, WINNER P et al.: Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache (2003) 43:214-222.
45. STEINER TJ, DIENER HC, MACGREGOR EA et al.: Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia (2003) 23:942-952.
46. BOMHOF M, PAZ J, LEGG N et al.: Comparison of rizatriptan 10 mg vs naratriptan 2.5 mg in migraine. Eur. Neurol. (1999) 42:173-179.
47. BATES D, WINTER P: Efficacy and tolerability of naratriptan tablets (0.1 - 2.5 mg) in the acute treatment of migraine. Eur. J. Neurol. (1998) 5:S48-S49.
48. HAVANKA H, DAHLÖF C, POP PHM et al.: Efficacy of naratriptan tablets in the acute treatment of migraine: a dose ranging study. Clin. Ther. (2000) 22:970-980.
49. GÖBEL H, WINTER P, BOSWELL D et al.: Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Clin. Then. (2000) 22:981-989.
50. TFELT-HANSEN P, TEALL J, RODRIGUEZ F et al.: Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache (1998) 38:748-755.
51. VISSER WH, TERWINDT G, REINES SA et al.: Rizatriptan vs sumatriptan in the acute treatment of migraine. Rizatriptan vs sumatriptan in the acute treatment of migraine. Arch. Neurol. (1996) 53:1132-1137.
52. GOLDSTEIN J, RYAN R, JIANG K et al.: Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache (1998) 38:737-747.
53. PASCUAL J, VEGA P, DIENER H-C et al.: Comparison of rizatriptan 10 mg vs zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia (2000) 20:455-461.
54. GALLAGHER RM, DENNISH G, SPIERINGS ELH et al.: A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache (2000) 40:119-128.
55. GERAUD G, OLESEN J, PFAFFENRATH V et al.: Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia (2000) 20:30-38.
56. THE MULTINATIONAL ORAL SUMATRIPTAN AND CAFERGOT COMPARATIVE STUDY GROUP: A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur. Neurol. (1991) 31:314-322.
57. THE ORAL SUMATRIPTAN AND ASPIRIN PLUS METOCLOPRAMIDE COMPARITIVE STUDY GROUP: A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur. Neurol. (1992) 32:177-184.
58. TFELT-HANSEN P, HENRY P, MULDER L et al.: The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet (1995) 346:923-926.
59. MYLLYÄ VV, HAVANKA H, HERRALA L et al.: Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache (1998) 38:201-207.
60. THE DICLOFENAC-K/SUMATRIPTAN MIGRAINE STUDY GROUP: Acute treatment of migraine attacks: efficacy and safety of nonsteriodal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia (1999) 19:232-240.
61. DIENER HC, JANSEN JP, RECHES A et al.: Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multi-centre, randomised, double-blind, placebo-controlled comparison. Eur. Neurol. (2002) 47:99-107.
62. DOWSON A, BALL K, HAWORTH D: Comparison of a fixed combination of domperidone and paracetamol with sumatriptan 50 mg in moderate-to-severe migraine: a randomised UK primary care study. Curr. Med. Res. Opin. (2000) 3:190-197.
63. GERAUD G, COMPAGNON A, ROSSI A et al.: Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three attack study. Eur. Neurol. (2002) 47:88-98.
64. SALONEN R, PETRICOUL O, SABIN A et al.: Encapsulation delays absorption of sumatriptan tablets. Cephalalgia (2000) 20:423-424.
65. SIKES C, MUIRHEAD N, ALDERMAN J et al.: In vivo disintegration characterictics of encapsulated and unencapsulated sumatriptan: results of a scintigraphy study in humans. Headache (2002) 42:399.
66. 1B/1D agonists) in the acute migraine treatment: a meta-analysis of 53 trials. Lancet (2001) 358:1668-1675.
67. PASCUAL J, FALK RM, PIESSENS F et al.: Consistent efficacy and tolerability of almotripran in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia (2000) 20:588-596.
68. DAHLÖF C, TFELT-HANSEN P, MASSIOU H et al.: Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology (2001) 57:1811-1817.
69. DIENER HC, GENDOLLA A, GEBERT I et al.: Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Fur. Neurol. (2005) 53(Suppl. 1):41-48.
70. STARK R, DAHLÖF C, HAUGHIE S et al.: Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a Phase III, multi-centre, placebo-controlled study across three attacks. Cephalalgia (2002) 22:23-32.
71. ELETRIPTAN STEERING COMMITTEE IN JAPAN: Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japananese migraineurs. Cephalalgia (2002) 22:416-423.
72. FÄRKKILÄ M, OLESEN J, DAHLÖF C et al.: Eletriptan for treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia (2003) 23:463-471.
73. SHEFTELL F, RYAN R, PITMAN V; FOR THE ELETRIPTAN STEERING COMMITTEE: Efficacy, safety, and tolerance of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache (2003) 43:202-213.
74. RYAN R, GERAUD G, GOLDSTEIN J et al.: Clinical efficacy of frovatriptan. Placebo-controlled studies. Headache (2002) 42(Suppl. 2):S84-S92.
75. RAPOPORT A, RYAN R, GOLDSTEIN J et al.: Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache (2002) 42(Suppl. 2):S74-S83.
76. KLASSEN A, ELKIND A, ASGHARNEJAD M et al.: Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache (1997) 37:640-645.
77. MATHEW NT: Naratriptan is effective and well tolerated in the acute treatment of migraine. Neurology (1997) 49:1485-1490.
78. TEALL J, TUCHMAN M, CUTLER N et al.: Rizatriptan (Maxalt) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, out-patient study. Headache (1998) 38:281-287.
79. GIJSMAN H, KRAMER MS, SARGENT J et al.: Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia (1997) 17:647-651.
80. AHRENS SP, FARMER MV, WILLIAMS DL et al.: Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia (1999) 19:525-530.
81. CADY R, MARTIN V, MAUSKOP A et al.: Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache (2006) 46:914-924.
82. CUTLER N, MUSHET GR, DAVIS R et al.: Oral sumatriptan for the acute treatment of migarine: evaluation of three dosage strenghts. Neurology (1995) 45:S5-S9.
83. SARGENT J, KIRCHNER JR, DAVIS R et al.: Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology (1995) 45(Suppl. 7):S10-S14.
84. PFAFFENRATH V, CUNIN G, SJONELL G et al.: Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache (1998) 38:184-190.
85. ORAL SUMATRIPTAN DOSE-DEFINING STUDY GROUP: Eur. Neurol. (1991) 31:300-305.
86. ORAL SUMATRIPTAN INTERNATIONAL MULTIPLE-DOSE STUDY GROUP: Eur. Neurol. (1991) 31:306-313.
87. GOADSBY PJ, ZAGAMI AS, DONNAN GA et al.: Oral sumatriptan in acute migraine. Lancet (1991) 338:782-783.
88. NAPPI G, SICUTERI F, BYRNE M et al.: Oral sumatriptan compared with placebo in the acute treatment of migraine. J. Neurol. (1994) 241:138-144.
89. TFELT-HANSEN P, HENRY P, MULDER LJ et al.: The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet (1995) 346:923-926.
90. REDERICH G, RAPOPORT A, CUTLER N et al.: Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology (1995) 45(Suppl. 7):S15-S20.
91. CENTONZE V, POLITO MB, DI BARI M et al.: Evaluation of the efficacy of oral sumatriptan in the therapy of acute migraine. Clin. Ther. (1995) 146:721-728.
92. THE S2BM09 STUDY GROUP: A study to compare the efficacy, safety and tolerability of oral sumatriptan 25, 50 and 100 mg dose in the acute treatment of migraine. Eur J. Neurol. (1996) 3(Suppl. 3):149-150.
93. DIENER HC, KLEIN KB; FOR THE MULTINATIONAL ORAL 311C90 AND SUMATRIPTAN COMPARATIVE STUDY GROUP: The first comparison of the efficacy and safety of 311C90 and sumatriptan in the treatment of migraine. 3rd European Headache Conference. (5 - 8 June 1996), Sardinia.
94. DIEZ-TEJEDOR E: Oral sumatriptan Spanish trial. Assessment of response consistency to oral sumatriptan in migraine attacks. Cephalalgia (1997) 17:412.
95. FERRARI MD: 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists. Neurology (1997) 48(Suppl. 3):S21-S24.
96. RAPOPORT AM, RAMADAN NM, ADELMAN JU et al.: Optimizing the dose of zolmitriptan for the acute treatment of migraine a multicener, double-blind, placebo-controlled. Dopse range finding study. Neurology (1997) 49:1210-1218.
97. SOLOMON GD, VADY RK, KLAPPER JA et al.: Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology (1997) 49:1219-1225.
98. TRAPEEZ: Data on file. Astra Zeneca. Study 37.
99. MATHEW NT, KAILASAM J, MEADORS L: Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache (2004) 44:669-673.
100. CARPAY J, SCHOENEN J, AHMAD F et al.: Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin. Ther. (2004) 26:214-223.
101. LANDY S, SAVANI N, SHACKELFORD S et al.: Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int. J. Clin. Pract. (2004) 58:913-919.
102. KLAPPER J, LUCAS C, ROSJO O et al.: Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia (2004) 24:918-924.
103. LODER E, FREITAG FG, ADELMAN J et al.: Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo-controlled trial. Curr. Med. Res. Opin. (2005) 21:381-389.
104. FERRARI MD: Should we advise patients to treat migraine attacks early: methodologic issues. Eur. Neurol. (2005) 53(Suppl. 1):17-21.
105. PASCUAL J: Efficacy and tolerability of almotriptan in postmarketing surveillance studies. Eur. Neurol. (2005) 53(Suppl. 1):34-40.
106. GENDOLLA A: Clinical profile and practice experience of almotriptan. Cephalalgia (2004) 24(Suppl. 2): 16-23.
107. MATHEW NT: Efficacy and tolerability of almotriptan in controlled clinical trials. Eur. Neurol. (2005) 53(Suppl. 1):29-33.
108. GERAUD G, SPIERINGS ELH, KEYWOOD C: Tolerability and safety of frovastriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache (2002) 42(Suppl. 2):S93-S99.
109. WINNER P, MANNIX LK, PUTNAM DG et al.: Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin. Proc. (2003) 78:1214-1222.
110. NETT R, LANDY S, SHACKELFORD S et al.: Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet. Gynecol. (2003) 102:835-842.
111. MYLLYLA VV, HAVANKA H, HERRALA L et al.: Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomised, controlled, parallel-group study. Headache (1998) 38:201-207.
112. KNUISTINGH NEVEN A, BARTELINK MEL, DE JONGH TOH et al.: NHG-standard Hoofdpijn. Huisarts Wet. (2004) 46:411-422.
113. TFELT-HANSEN P, SAXENA PR, DAHLÖF C et al.: Ergotamine in the acute treatment of migraine. A review and European consensus. Brain (2000) 123:9-18.
114. GOADSBY PJ, MASSIOU H, PASCUAL J et al.: Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol. Scand. (2007) 115:34-40.